We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current CRL market cap is 11.76B. The company's latest EPS is USD 9.2430 and P/E is 24.77.
| Quarter End | Jun 2022 | Sep 2022 | Apr 2023 | Jul 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 973.13M | 989.16M | 1.03B | 1.06B | 1.03B |
| Operating Income | 187.41M | 150.98M | 167.89M | 163.88M | 151.5M |
| Net Income | 109.32M | 96.47M | 103.13M | 97.02M | 87.39M |
| Year End 30 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.62B | 2.92B | 3.54B | 3.98B | 4.13B |
| Operating Income | 351.15M | 432.73M | 589.86M | 650.98M | 617.26M |
| Net Income | 252.02M | 364.3M | 390.98M | 486.23M | 474.62M |
| Quarter End | Jun 2022 | Sep 2022 | Apr 2023 | Jul 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 7.53B | 7.38B | 7.7B | 7.77B | 7.61B |
| Total Liabilities | 4.84B | 4.71B | 4.54B | 4.47B | 4.26B |
| Total Equity | 2.65B | 2.63B | 3.11B | 3.26B | 3.31B |
| Year End 30 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 4.69B | 5.49B | 7.02B | 7.6B | 8.2B |
| Total Liabilities | 3.03B | 3.35B | 4.43B | 4.58B | 4.54B |
| Total Equity | 1.64B | 2.12B | 2.54B | 2.98B | 3.6B |
| Quarter End | Jun 2022 | Sep 2022 | Apr 2023 | Jul 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 252.1M | 384.88M | 109.38M | 257.51M | 462.96M |
| Investing | -560.12M | -652.31M | -168.62M | -245.23M | -324.78M |
| Financing | 258.15M | 206.56M | 25.24M | -46.22M | -209.09M |
| Year End 30 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 480.94M | 546.58M | 760.8M | 619.64M | 683.9M |
| Investing | -681.5M | -601.54M | -1.44B | -607.92M | -563.16M |
| Financing | 231.94M | 47.25M | 672.6M | -42.4M | -85.52M |
| Market Cap | 11.76B |
| Price to Earnings Ratio | 24.77 |
| Price to Sales Ratio | 2.85 |
| Price to Cash Ratio | 42.49 |
| Price to Book Ratio | 3.21 |
| Dividend Yield | - |
| Shares Outstanding | 51.35M |
| Average Volume (1 week) | 605.45k |
| Average Volume (1 Month) | 506.81k |
| 52 Week Change | 23.09% |
| 52 Week High | 275.00 |
| 52 Week Low | 161.65 |
| Spread (Intraday) | 48.97 (19.04%) |
| Company Name | Charles River Laboratories International Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.criver.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
